Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
13 nov. 2024 16h05 HE
|
Tarsus Pharmaceuticals, Inc
Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two...
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
13 nov. 2024 08h30 HE
|
Tarsus Pharmaceuticals, Inc
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus...
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
06 nov. 2024 16h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
05 nov. 2024 08h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address unmet medical needs and apply proven science and new technology to...
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
17 oct. 2024 08h30 HE
|
Tarsus Pharmaceuticals, Inc
Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients’ eyelids Demodex blepharitis is a significant eyelid disease that impacts...
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
25 sept. 2024 17h00 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
28 août 2024 17h00 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
08 août 2024 16h05 HE
|
Tarsus Pharmaceuticals, Inc
Generated $40.8 million in XDEMVY® net product sales in the second quarter and $65.5 million year-to-date Delivered more than 37,000 bottles of XDEMVY to patients in the second quarter Delivered an...
Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
29 juil. 2024 16h30 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
Tarsus to Participate in Upcoming Investor Conferences
29 mai 2024 17h00 HE
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...